341 related articles for article (PubMed ID: 18497949)
1. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
[TBL] [Abstract][Full Text] [Related]
2. N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.
Matsueda S; Gao H; Efferson CL; Tsuda N; Ishiyama S; Li Y; Ioannides MG; Fisk B; Peoples GE; Ioannides CG
Anticancer Res; 2009 Jul; 29(7):2427-35. PubMed ID: 19596910
[TBL] [Abstract][Full Text] [Related]
3. Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines.
Li Y; Matsueda S; Efferson CL; Tsuda N; Kawano K; Gao H; Peoples GE; Ioannides CG
Anticancer Res; 2009 Jan; 29(1):41-58. PubMed ID: 19331132
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG
Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296
[TBL] [Abstract][Full Text] [Related]
6. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL
Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833
[TBL] [Abstract][Full Text] [Related]
7. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
8. [The characteristics of anti-B-cell malignance cytotoxic T lymphocytic clones induced by lymphoma relative peptides].
Guo XL; Zhu P; Zhu X; Liu J; Ou Y; Du JW
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1476-80. PubMed ID: 16061026
[TBL] [Abstract][Full Text] [Related]
9. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
10. Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-gamma: IL-10 balance.
Lee TV; Johnston DA; Thomakos N; Honda T; Efferson CL; Ioannides CG
Anticancer Res; 2002; 22(3):1481-90. PubMed ID: 12168827
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG
Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901
[TBL] [Abstract][Full Text] [Related]
12. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes.
Dangles V; Halberstam I; Scardino A; Choppin J; Wertheimer M; Richon S; Quelvennec E; Moirand R; Guillet JG; Kosmatopoulos K; Bellet D; Zeliszewski D
Cancer Immunol Immunother; 2002 Feb; 50(12):673-81. PubMed ID: 11862419
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
15. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose?
Kiecker F; Streitz M; Ay B; Cherepnev G; Volk HD; Volkmer-Engert R; Kern F
Hum Immunol; 2004 May; 65(5):523-36. PubMed ID: 15172453
[TBL] [Abstract][Full Text] [Related]
17. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.
Fisk B; Hudson JM; Kavanagh J; Wharton JT; Murray JL; Ioannides CG; Kudelka AP
Anticancer Res; 1997; 17(1A):45-53. PubMed ID: 9066629
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
[TBL] [Abstract][Full Text] [Related]
19. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements of peptide and MHC for DR(alpha, beta 1*0401)-restricted T cell antigen recognition.
McNicholl JM; Whitworth WC; Oftung F; Fu X; Shinnick T; Jensen PE; Simon M; Wohlhueter RM; Karr RW
J Immunol; 1995 Aug; 155(4):1951-63. PubMed ID: 7636246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]